Company News Summary
Mayne Pharma Group Provides 2018 Full Year Results Investor Presentation
24 Aug 2018 | 09:25:00 | Associate analysts | Increase | Decrease | 
Original announcement: 2018 Full Year Results Investor Presentation
Mayne Pharma Group reported EBITDA of A$116.8m and adjusted EBITDA of A$165.3m. Its net loss after tax of A$(133.9)m was driven by asset impairments and other one off adjustments incurred in 1HFY 2018. Generic Products Division performed strongly in the second half driven by new product launches, normalised levels of stock obsolescence, portfolio optimisation and cost savings from the transfer in of Teva acquired products. Specialty Brands Division expanded its dermatology field force to 114 sales reps which drove stronger sales performance of Fabior and Sorilux up 67% and 110% respectively on FY 2017.
See more ASX300 News Announcements